In vitro assessment of cytochrome P450 inhibition: Strategies for increasing LC/MS-based assay throughput using a one-point IC50 method and multiplexing high-performance liquid chromatography

Journal of Pharmaceutical Sciences

Volumn 96, Issue 9, 2007, Pages 2485-2493

  Lin, Tong ^a   Pan, Kristine ^b   Mordenti, Joyce ^c   Lin, Pan ^d  

^a Affymax ^*  (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

^c Institute for OneWorld Health   (United States)

^d InterMune   (United States)

Author keywords

Cytochrome P450; Drug metabolizing enzymes; Drug drug interactions; High throughput technologies; Human liver microsomes; Inhibition; Mass spectrometry; Mathematical model; One point IC50; Probe substrates

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; FURAFYLLINE; KETOCONAZOLE; MEPHENYTOIN; MIDAZOLAM; PHENACETIN; QUINIDINE; SULFAPHENAZOLE; TESTOSTERONE; TRANYLCYPROMINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INHIBITION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; INHIBITION KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; SCREENING;

EID: 34748879042     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20884     Document Type: Article

References (21)

1. Smith DA, Abel SM, Hyland R, Jones BC. 1998. Human cytochrome P450s: Selectivity and measurement in vivo. Xenobiotica 28:1095-1128.
2. Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. 2002. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In: Rodrigues AD, editor. Drug-Drug Interactions. New York: Marcel Dekker Inc. pp 217-294.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach SR, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin Pharmacol 43:443-469.
4. Obach RS, Walsky RL, Venkatakrishnan K, Gaman EA, Houston JB, Tremaine LM. 2006. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 316:336-348.
5. Crespi CL, Miller VP, Penman BW. 1997. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes. P450. Analytical Biochemistry 248:188-190.
6. Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, Liu D. 2006. Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol 2:629-645.
7. White RE. 2000. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Annu Rev Pharmacol Toxicol 40: 133-157.
8. Ayrton J, Plumb R, Leavens WJ, Mallett D, Dickins M, Dear GJ. 1998. Application of a generic fast gradient liquid chromatography tandem mass spectrometry method for the analysis of cytochrome P450 probe substrates. Rapid Commun Mass Spectrom 12:217-224.
9. Food and Drug Administration Draft Guidance for Industry. 2006. Drug interaction studies - Study design, data analysis, and implications for dosing and labeling. US Department of Health and Human Services (http://www.fda.gov/ cber/ guidelines.htm.)
10. Yuan R, Parmelee T, Balian JD, Uppoor RS, Ajayi F, Burnett A, Lesko LJ, Marroum P. 1999. In vitro metabolic interaction studies: Experience of the Food and Drug Administration. Clin Pharmacol Ther 66:9-15.
11. Tucker GT, Houston JB, Huang SM. 2001. Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 18:1071-1080.
12. Yuan R, Madani S, Wei XX, Reynolds K, Huang SM. 2002. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab Dispos 30:1311-1319.
13. Bu H, Magis L, Teitelbaum KKP. 2001. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6, and 2 E1. Rapid Commun Mass Spectrom 15:741-748.
14. Weaver R, Graham KS, Beattie IG, Riley RJ. 2003. Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos 31:955-966.
15. Cheng Y, Prusoff WH. 1973. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
16. Patki KC, Moltke LL, Greenblatt DJ. 2003. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: Role of CYP3A4 and CYP3A5. Drug Metab Dispos 31:938-944.
17. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clark SE, Chenery RJ. 1995. Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2 C9. Xenobiotica 25:261-270.
18. Rodrigues AD, Roberts EM. 1997. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6). Drug Metab Dispos 25:651-655.
19. Yin H, Racha J, Li SY, Olejnik N, Satoh H, Moore D. 2000. Automated high throughput human CYP isoform activity assay using SPE-LC/MS method: Application in CYP inhibition evaluation. Xenobiotica 30:141-154.
20. Bu H, Magis L, Teitelbaum KKP. 2001. High-throughput cytochrome P450 (CYP) inhibition screening via cassette probe-dosing strategy II. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP2D6 inhibition assessment. J Chromatogr B 753:321-326.
21. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE. 2001. A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metab Dispos 29:23-29.